Author Archives: Admin

Kraig Biocraft Laboratories Signs Pivotal MOU in Vietnam’s Silk Production Capital

ANN ARBOR, Mich., – January 30, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”), signs key Memorandum of Understanding (MOU) with the Vietnam Sericulture Association (VSA) and the Lam Dong Agro-Forestry Research Experiment Center (LAREC). This collaboration is designed to enhance and expand silk production in Vietnam. 

The agreement is the result of many years of work, culminating in a highly productive working session held between Kraig Labs senior management, the VSA, the LAREC, various VSA members, and Prodigy Textiles, the Company’s Vietnamese subsidiary. Under the guidance of this MOU, the Company will partner with these leading agencies to enhance and expand Vietnam’s silk production. 

“We have been working with various governmental ministries, agencies, and departments for an extended period of time in order to demonstrate our silk production technology and to tailor that technology to the local environment,” said Company founder and CEO, Kim K. Thompson. “The MOU, and the collaboration it represents, opens up new opportunities for advanced fiber commercialization. Our goal now is to meet the challenge of expanding spider silk production to commercial scale in 2024.” 

In addition to this pivotal partnership with the VSA and the LAREC, Kraig Labs also reports that it is working aggressively to expand its production capacities and footprint in the first quarter of 2024. The Company’s plan is to achieve metric-ton production of spider silk later this year.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Targets Vertical Markets for its Spider Silk and Shares Planned Applications 

ANN ARBOR, Mich., – January 22, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”), shares an update on near-term commercial applications and opportunities for recombinant spider silk as the Company prepares for expanding production in 2024. Spider silk has long been prized for its unique blend of chemical and mechanical properties, including strength and elasticity.

Kraig Labs is currently in the process of ramping up production trials of its recombinant spider silk under the trademark Dragon SilkTM. The move to ramp up production follows on the heels of the Company’s successful early production test announced in December.

During the ramp-up phase, while production quantities are relatively limited, the Company is targeting end-product applications in fashion and performance apparel. “Because production quantities will be relatively limited during the early stages of the production ramp-up, and because we will have control of that limited supply of Dragon Silk, it makes sense for us to focus on markets where we can control the end use of the Dragon Silk That will allow us to potentially share in a portion of the value-added manufacturing and distribution beyond the creation of the recombinant spider silk itself,” said Company Founder and CEO, Kim Thompson. “In essence, we are looking for partial vertical integration in these early spider silk products to maximize our market position.”

As production quantities increase, the Company expects to begin addressing demand from additional market segments, including:

  • Engineering textiles
  • Composites
  • Cosmetics
  • Defensive and protective textiles
  • Bio-plastics that are biodegradable and bio-compatible
  • Fiber optics
  • Medical textiles, fibers, ligaments, wound dressings, skin grafts, and tissue engineering

The Company believes that the enhanced strength and toughness of its Dragon Silk line of materials, combined with their bio-degradable and biocompatible properties, will be able to address existing material needs in these markets and many more.

Kraig Labs has already begun early-stage exploration into bio-plastics, medical textiles, cosmetics & defensive textile applications and expects to accelerate work in these fields as production of spider silk increases.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Joins Vietnam Sericulture Association

ANN ARBOR, Mich., Jan. 9, 2024– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, today announces its Vietnamese subsidiary, Prodigy Textiles (“Prodigy”), has joined the Vietnam Sericulture Association (“VSA”).

Kraig Labs’ and Prodigy’s senior management met with leaders of the VSA in December. These meetings took place during the Company’s management review of current operations and planned expansion of recombinant spider silk production in 2024. 

The Company is excited to work with the VSA and support their vision for enhancing silk production and strengthening overall sericulture in Vietnam. 

“Joining the Vietnam Sericulture Association is part of Kraig Labs’ commitment to building strong ties within the sericulture industry and expanding our operational role in the continued growth of Vietnam as a global leader in silk production,” said company Founder and CEO, Kim Thompson. “We believe that there is a very large potential to increase and grow Vietnam’s silk production, and we are working to make our recombinant spider silk a part of that growth.” 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. ( www.KraigLabs.com ), a reporting biotechnology company, is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward-Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward-looking statements include descriptions of the Company’s

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Season’s Greetings from Kraig Labs’ CEO, Kim Thompson

The holiday season is here, and with it, the opportunity to reflect on the past year’s accomplishments and challenges.

We started 2023 with a concentrated program to strengthen our production silkworm strains with the goal of increasing their robustness and tolerance for the commercial production environment. We undertook this program because our study of our previous attempts to ramp up production indicated that our laboratory strains may have been overly inbred or otherwise lacked the necessary robustness to carry out our production objectives.

This process involved selective breeding over many generations and isolating target traits while crossbreeding with more robust specimens. The ultimate goal was to create two, and ultimately four, separate strains of our silkworm, which, when crossed with each other, would produce significant hybrid vigor. This program has been very successful.

That success, along with the items described below, has positioned us well for 2024. Over the past year, we have created nine new silkworm strains to improve robustness. We are now concentrating on six of those strains, half of which are ready or nearly ready for field trials. One of those strains is already homozygous for the spider silk transgene, and we expect two more strains to be homozygous within two more generations.

We performed an early field test with two of these strains, as described in a recent press release. The results greatly exceeded our expectations. This testing with a two-strain hybrid created the largest caterpillars and cocoons Kraig Labs has ever produced. As we look to the 2024 silk-producing season, these new lines will become the bedrock upon which future production is built. We have additional strains in earlier stages of development that we hope to roll out in the third or fourth quarter of 2024 for double hybrid production.

While our core focus remains on the immediate commercialization of existing spider silk technologies, our molecular biology team continues to work on the next generation of materials. This work continues to advance forward but is moving more slowly than we had hoped. This delay is primarily related to our transition to more advanced technology platforms. Our work is now focused on larger, more complex silk protein designs as well as newer splicing technologies that have challenged our team. We had hoped to announce the creation of a new transgenic in November, but we have not hit that mark. We will add additional resources to our molecular biology team in early 2024 to speed up this process. We remain confident in our ability to further improve our spider silks and obtain goals which we have not yet publicly announced. As new transgenics are produced and verified, we will continue to share those updates with you.

As I sit down to write this year in review update, I have just returned from a very successful trip to Vietnam. I come to you today re-invigorated by the exciting opportunities ahead for Kraig Labs, our shareholders, and spider silk. A recent small-scale test of changes in our production system was successful. In the process of that test, we also learned how we can improve our procedures and business model beyond mere silkworm robustness to achieve our production objectives. We have active negotiations in process with public and private sector actors, which would have been unimaginable six months ago.

I founded Kraig Labs with the vision of becoming a world leader in the bio-engineering of spider silk. Our team met that challenge by creating our silkworm-based spider silk production platform, by creating Dragon SilkTM, and now the six new production strains we created in 2023. Our core competency has been molecular biology. Our shortfall has been translating our successes in the laboratory to sericulture and production success outside of that environment.

Through our work at our subsidiary, Prodigy Textiles, we have come to better understand the global silk industrial base and the narrow pinch-points in silk manufacturing. Nearly all global silk production results from silkworm eggs produced in either India or China and then shipped worldwide. This is a matter of critical importance which directly affects the nature of sericulture as practiced in virtually all other countries. The breeding of silkworms and the production of eggs is a highly specialized and narrowly concentrated skill set that goes beyond hatching silkworms and rearing them for production.

In Vietnam, there has traditionally been little to no silkworm egg production for mass commercialization. The importance of mastering egg production cannot be overstated, and it is an area where our efforts were falling short. We are investing considerable resources to become world leaders in this field as well. While we have always done breeding and egg production in our laboratories, we found, through the school of hard knocks, that our skill sets in this area did not translate outside of the environmentally controlled lab.

Kraig Labs has now engaged leading experts from India to assess, train, and revamp our domestic and international operations to meet the exacting standards used in India’s commercial silk operations. These leaders in their field, from the fastest-growing silk producer in the world, are now advising us on all aspects of our sericulture operations, from breeding and strain development to disease screening and management. We expect to bring them to our overseas operations in early 2024 to work hand in hand with our team as we drive toward our target of metric-ton spider silk production.

These experts have already brought much clarity to the hows and whys of past production shortcomings. While the robustness of our silkworms was a factor, it was not the only factor. With their help, we are now establishing control over those variables. My commitment to making Kraig Labs a world-class organization means having the absolute best people. Our team of consultants from India represents the out-and-out best of the best when it comes to metric-ton scale silk production.

With our new friends from India and the opportunities that lie before us, we plan to make 2024 the greatest year yet for Kraig Labs and the commercialization of spider silk. We are very excited to get to work in 2024, unlocking the potential of this enterprise. It is from that perspective that we look forward to the New Year and new horizons.

From our team at Kraig Labs, we hope your holiday season is spent with loved ones and filled with joy. We thank you for your continued support as we work to revolutionize the textile industry and deliver the incredible opportunities that await our spider silk.

Season’s Greetings, Happy New Year, Merry Christmas, and Happy Hanukkah to all our shareholders and the world.

Kim Thompson and the entire Kraig Labs’ family

This entry was posted on by .

Kraig Biocraft Laboratories Announces Successful Production Test Utilizing a Two Strain Hybrid System

ANN ARBOR, Mich., – December 19, 2023 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, today announces that it has successfully completed the first pilot production test using a new two strain hybrid system. 

The two strain hybrid system was successfully tested using an early version of Kraig Labs’ new hybrid production model slated for trials this spring. The pre-trial test of the early version of the hybrids was conducted in order to obtain preliminary data before moving to the next step. The Company’s analysis of the first generation of early production hybrids confirms their increased vigor and significantly increased cocoon size.

“This early version of our hybrid system was tested specifically to confirm that we are on track for our spring trials,” said company CEO and Founder Kim Thompson. “The resulting silkworms as well as the resulting cocoons, were the largest I have ever seen in our production. This is critical,” Thompson continued, “because cocoon size translates directly to increased silk yield and production efficiency. In my view, silkworm size is also a very good indicator of silkworm health. We needed to see good results before committing resources to the upcoming field trials. These results greatly exceed our expectations. Just as significantly, we have been doing a lot of work and research to improve the robustness of our stains. This preliminary data strongly suggests that we are hitting that target as well.”

This advancement in the Company’s commercialization of recombinant spider silk will significantly increase silk production per rearing cycle and will likely improve the quality of the finished silk.  

The Company is now planning to transition all of its spider silk production to a two strain hybrid model in the near term. The Company hopes to be able to utilize even more advanced hybrids before the end of the upcoming field trials.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward-Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward-looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Announces Early Start to Production Season with Successful Small Batch Delivery of Spider Silk

ANN ARBOR, Mich., – December 14, 2023 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, today announces the early start to the production season with the successful manufacture and delivery of the most recent batch of recombinant spider silk.  Silk from this production cycle was processed into finished reeled raw silk and happily received on-site by the Company’s Senior management this week. 

The delivery of this silk further reinforces the Company’s production model.  With this success, the Company is now accelerating its plans for the upcoming 2024 production season and beyond.

“I am very excited to have produced this small batch ahead of our upcoming field trials scheduled for this spring.  This early production bodes very well for the pending trials, and indicates, to me, that we are well on track to meet our 2024 production targets.  The purpose of the recently completed production batch was to test our production model.  The purpose of the upcoming field trials is to gain data from hybrids which we have developed over the last 12 months. Having those two pieces working together is key to commercial scale production.” said CEO and Founder Kim Thompson.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward-Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward-looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Prepares for Silk Production Season

ANN ARBOR, Mich., – December 06, 2023 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, today announced that its senior management team is en route to Vietnam to prepare for the spring rearing season.  They will meet with the team from its wholly owned Vietnamese subsidiary, Prodigy Textiles, third-party contractors, and government officials, including provincial leadership.

This trip will lay the groundwork for the upcoming spring rearing season, strengthening its team, and preparing its facilities.  The Company is leveraging the winter offseason to align its staff and contractors to ensure ideal conditions for the launch of the 2024 season.  Senior management will also meet with hatcheries and spinners to look for opportunities to expand the Company’s integration into the supply chain and to vet additional production locations and partners, for 2024 and beyond.

Kraig Labs U.S. team just concluded a very productive month of onsite work with it senior sericulture consultant for India. Following up on that work, management plans to implement advanced rearing protocol across all of its operations domestically and overseas. The Company also plans to bring these consultants to Vietnam in the spring of 2024 to work directly with its production team as the Company builds out its capabilities.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward-Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward-looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Strengthens Spider Silk Production Operations with Sericulture Experts from India

ANN ARBOR, Mich., – November 27, 2023 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, today announced its continued investment into building its world-class team with the addition of leading sericulture consultants from India. Before joining Kraig, these individuals spent more than 30 years in senior-level positions overseeing all aspects of India’s silk production on a national scale.

The first of these experts is currently at Kraig’s R&D headquarters for 30 days of hands-on work with the team to provide onsite training for technical staff, strengthen its rearing operation fundamentals, and support the field testing of our production operations. 

Following the overhauling of U.S. operations and providing production-oriented training with its U.S. staff, the Company plans to bring these technical experts to review and overhaul its overseas operations and facilities. The primary focus is to improve production yields and increase throughput.

Kraig Labs assembled this team of outside production experts to address all aspects of spider silk production, including new strain development and purification, optimizing and selection of ideal hybrid breed pairing, disease prevention and screening, construction and management of rearing facilities, and large-scale production.

“We believe that building the best team means assembling the absolute best people, in both gene engineering and production. I am delighted to welcome some of the best minds in silk production from around the world to support our operations in the U.S. and overseas,” said Kraig Labs COO Jon Rice. “We are already implementing significant changes in our U.S. operations based on their recommendations, and I look forward to integrating their expertise into our production operations as we prepare for Spring field trials.”

The Company is actively developing numerous pure-line silkworm strains utilizing its recombinant spider silk technology. One key area of focus for work at Kraig Labs’ overseas production operations with these new experts will be testing and creating the optimal pairing of these pure-line strains to produce ideal hybrid cocoons and spider silk. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward-Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward-looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Creates Synergy by Onboarding Key Elements and Scientists from the University of Notre Dame Spider Silk Research Operations

ANN ARBOR, Mich., – October 12, 2023 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, today announced that it hired key scientists from the University of Notre Dame (“UND”) spider silk research lab following the retirement of Dr. Malcolm Fraser, Professor Emeritus. Onboarding their expertise and blending it with the Company’s R&D operations has created significant synergies in both molecular biology and sericulture. 

This merger of Kraig Labs operations with significant elements, including scientific personnel, from the UND Fraser Lab, comes after more than a decade of close collaboration between Kraig Labs and the University that created the Company’s first spider silk transgenics, including Monster Silk® and Dragon Silk®.

The core technologies initially envisioned by the Company’s Founder and CEO, Kim Thompson, were first driven to practice in the UND labs, creating the first recombinant silkworms spinning spider silk. Following that success, the Company opened its R&D headquarters and has been advancing the state of spider silk transgenics utilizing the latest gene editing technologies.

Integrating members from the UND spider silk research program into Kraig Labs’ R&D operations further strengthens the Company’s expertise and leading role in commercializing cost-effective and eco-responsible spider silk manufacturing.

“I’m very excited to see the continuation of the groundbreaking work in recombinant spider silk that was developed in my lab at Notre Dame,” said Dr. Fraser. “The merger of these two teams holds great promise for the future spider silks. Our collaborations over the last decade have created incredible advancements in recombinant spider silk and transgenic silkworms. I am delighted to see Kraig Labs beefing up its team and increasing the depth of its sericulture expertise as it prepares for larger-scale production of spider silk,” continued Dr. Fraser.

The Company continues to develop new and exciting spider silk technologies utilizing its readily scalable silkworm-based production model. The effect of merging these two industry-leading operations is expected to advance next-generation transgenics development rapidly and strengthen the Company’s international production operations.

“From my initial development of these concepts to our collaboration with Notre Dame and the resulting scientific breakthroughs, we have had one clear vision: large-scale production and commercialization of spider silks,” said Founder and CEO, Kim Thompson. “At each stage in this process, we have faced unique hurdles. Now, as we work to achieve larger-scale production of spider silks, we are harnessing the opportunity to expand our team with scientists from the Fraser Lab with a proven history of success in spider silk development. We are proud to announce that we are fully integrating key members of Fraser’s spider silk program into our operations. This has given us a tremendous needed boost to our operations as we prepare for the successful relaunch of spider silk production.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward-Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward-looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Announces Management Changes and Recalibration at its Vietnam subsidiary, Prodigy Textiles, to Support Production of Spider Silk

ANN ARBOR, Mich., – October 2, 2023 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, today announced a shakeup of the management of its Vietnamese subsidiary, Prodigy Textiles (“Prodigy”). The changes in management personnel and the implementation of new procedures are intended to refocus and re-energize Prodigy, as the Company’s silkworm breeding and egg production/distribution center to support large-scale spider silk manufacturing.

These changes are part of the Company’s larger efforts to optimize operations and fulfill its vision to commercialize spider silk using its scalable, cost-effective, and eco-responsible technologies.

Prodigy’s day-to-day will be led by its new general manager under the supervision of Kraig Labs’ COO. Mr. Ken Le will retain his position as Prodigy Textiles Director, focusing on business development and government relations. The Company is also replacing Prodigy’s head of sericulture and onboarding industry expertise.

“These steps, designed to improve efficiencies and encourage innovation, were taken after thoroughly assessing Prodigy’s operations, procedures, and management,” said COO Jon Rice. “The spider silk technologies developed at Kraig Labs are ready for large-scale production. I am confident that the changes we are making at Prodigy will provide the platform for that growth.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward-Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward-looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .